Cybin

Cybin is a public for-profit company that aims to deliver psychedelics (psilocybin) via a sublingual delivery mechanism. The company aims to start clinical trials within the year (2021).

Cybin

“Our mission is to bring fungi derived psychedelic and medicinal products into the world that may potentially drive the next discovery phase of life-changing medications to treat mental illness and other health conditions.”

The company wholly owns several other companies, namely Serenity Life Sciences Inc. (research) and Natures Journey Inc. (medical/consumers).

The company works together with a drug delivery company, and ATAI subsidiary, IntelGenx, to develop its products. The benefit of the sublingual strip may be the more convenient delivery method that may possibly even be more consistent over capsules or other methods.

In October 2020, the company raised $45 million Canadian and will do a reverse takeover (RTO, a relatively easy way to go public) of Clarmin to list on the TSXV. The company was also funded (in part) by Synaptic Ventures.

Since then, Cybin has raised a total of $98 million in funding over 5 rounds. Their latest funding was raised on Jul 27, 2021 from a Post-IPO Equity round.

The company is listed on the NYSKET under the ticker CYBN.

In December 2020, the company bought Adelia Therapeutics, a biopharmaceutical company, for $15.75 million.

Key Staff

News

Company Information

Cybin Website

Founded
December, 2019

Operational
Yes

Activities
B2B B2C Pharmaceutical Biotech

Topics of Interest
Anxiety

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships

Related Course(s)

EMBARK Open Access
EMBARK Open Access is a comprehensive course designed to equip care providers with the skills and knowledge to provide ethical, culturally competent, and trauma-informed psychedelic facilitation.

Company News

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT (Biospace, 13 April 2022)


Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial (The Dales Report, 29 March 2022)


Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder (Businesswire, 27 June 2022)


Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder (Yahoo Finance, 09 June 2022)


Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain (Businesswire, 31 March 2022)


Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder (BioSpace, 21 April 2022)


Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program (Financial Post, 03 June 2022)


Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder (BioSpace, 31 May 2022)


Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies (, 25 June 2024)
Cybin today announced the completion of its 74th pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies.

Cybin target raised at Oppenheimer after psilocybin data from Compass Pathways (, 25 June 2024)


Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities (, 23 November 2021)


Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model (, 30 November 2021)


Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder (, 25 June 2024)


Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders (, 15 December 2021)


Cybin Earns Notice Of Allowance For CYB004 (, 21 December 2021)


Location

HQ / Office 5600-100 King St W, Toronto, ON M5X 1C9, Canada
?>